3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
4
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
4
Polycythemia Vera
1
Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
80
Nivolumab
60
Sunitinib
59
Sorafenib
36
Everolimus
32
pazopanib
30
Axitinib
27
cabozantinib
25
Ipilimumab
24
Bevacizumab
24
atezolizumab
20
belzutifan
19
lenvatinib
16
avelumab
13
Paclitaxel
10
Docetaxel
9
temsirolimus
8
Cyclophosphamide
8
spartalizumab
7
fludarabine
7
Interleukin-2
7
Interferon alpha-2
7
tivozanib
6
durvalumab
6
Cetuximab
6
cemiplimab
5
aldesleukin
5
Ramucirumab
5
CB-839
5
bempegaldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Renal Cell
×
peginterferon alfa-2b
×
Clear all
NCT02089685
2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2
Completed
295 enrolled
25 charts